Annual report pursuant to Section 13 and 15(d)

Indefinite-Lived Intangible Assets and Other Long-Term Assets

Indefinite-Lived Intangible Assets and Other Long-Term Assets
12 Months Ended
Dec. 31, 2021
Goodwill and Intangible Assets Disclosure [Abstract]  
Indefinite-Lived Intangible Assets and Other Long-Term Assets


6. Indefinite-Lived Intangible Assets and Other Long-Term Assets


Indefinite-Lived Intangible Assets


The Company’s indefinite-lived intangible asset, OncoHist, is IPR&D relating to the Company’s business combination with SymbioTec in 2012. IPR&D is tested for impairment whenever events or changes in circumstances indicate that the carrying value may not be recoverable, although it is to be tested at least annually until the project is completed or abandoned. The Company completed an impairment analysis of the IPR&D during 2020 and concluded that the following factors indicated that the IPR&D was impaired: a decision by management to delay indefinitely any further development of the IPR&D and to not support the underlying intellectual property; the failure to sell or license the IPR&D to a third party; and the reduction in market capitalization. During the year ended December 31, 2020, the Company recorded an asset impairment charge of $9.2 million, which is presented within operating costs and expenses in the consolidated statements of comprehensive loss, representing the excess of the IPR&D asset’s carrying value over its estimated fair value. A reconciliation of the change in the carrying value of Indefinite-Lived Intangible Assets is as follows:  

Balance as of January 1, 2020   $ 9,243,128  
Impairment     (9,243,128 )
Balance as of December 31, 2020   $  


Other Long-Term Assets


In 2016, the Company entered into an agreement with Serum Institute for the prepayment of clinical PSA supply in exchange for the Company’s common stock. As of December 31, 2021 and 2020, the Company has classified $0.7 million of prepaid clinical supply as long-term as it does not anticipate utilizing the majority of the PSA supply within the next 12 months. No clinical supply was utilized during the years ended December 31, 2021 and 2020.


See also Note 14, Related Party Transactions for a description of the Pharmsynthez Loan.